NIH Exploratory Trials - Parkinson's Disease

描述(由申请人提供)：Net-PD项目是一个合作项目，包括NINDS和北美大约50个其他网站，进行临床试验，旨在开发预防帕金森氏病(PD)进展的药物。在该项目的初始阶段，完成了四种化合物(辅酶010、肌酸、GPI-1485和米诺环素)的两项无效性研究(FS1、FS-TOO)，导致正在进行的肌酸与安慰剂的LS1研究。第三个无效性试验(FS区)也已经启动，比较了吡格列酮和安慰剂。LS1研究预计将于2015年完成，FS-ZONE研究预计将于2014年完成。希望这些试验将显示帕金森病的运动和非运动特征的药理学益处，并将获得更多关于临床试验开发和一般帕金森病的知识。

DESCRIPTION (provided by applicant): The NET-PD project is a collaborative effort including NINDS and approximately 50 other sites in North America to conduct clinical trials aimed at developing agents to prevent progression of Parkinson's disease (PD). Two futility studies (FS1, FS-TOO) of four compounds (coenzyme 010, creatine, GPI-1485, and minocycline) were completed in the initial stages of this project, leading to the ongoing LS1 study of creatine versus placebo. A third futility trial (FS-ZONE) has also been initiated comparing pioglitazone versus placebo. The LS1 study is expected to be completed in 2015, and the FS-ZONE study is expected to be completed in 2014. It is hoped that these trials will demonstrate pharmacologic benefits in both motor and non-motor features of PD, and additional knowledge will be gained about clinical trial development and PD in general.